Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo

Alzheimer Disease Clinical Trial

Official title:

A Multi-centre, Double-blind, Parallel-group, Randomized Controlled Study to Investigate the Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Alzheimer Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02240693
• Other study ID #: 1289.5
• Secondary ID: 2013-005031-24
• Status: Completed
• Phase: Phase 2
• Start date: January 15, 2015
• Est. completion date: October 9, 2017

Study information

• Verified date: October 2018
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is designed to compare the effects of 4 different doses of orally administered BI 409306 to placebo in patients with Alzheimers Disease

Recruitment information / eligibility

• Status: Completed
• Enrollment: 128
• Est. completion date: October 9, 2017
• Est. primary completion date: September 18, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 55 Years and older

Eligibility

Inclusion criteria:

• Male and female patients with an age of at least 55 years

• Body weight not lower than 50 kgs

• Patients with a confirmed diagnosis of prodromal Alzheimer's Dementia (AD) on neuropsychological testing defined as:

Mini-Mental State Examination (MMSE) score: greater or equal 24 and a global Clinical Dementia Rating (CDR)-score of 0 or 0.5 and

Free and Cued Selective Recall Reminding Test (FCSRT) score:

free recall test: lower or equal 20 (out of 48) and total recall test: lower or equal 42 (out of 48)

Patients who do not reach the required score in FCSRT will additionally perform the Wechsler Memory Visual Paired Associates test. If the Wechsler Memory Visual Paired Associates test shows a cognitive deficit worse than 1 standard deviation to the mean (compared to the reference values of age and educational norms for inclusion), then the patients can be considered to be eligible for the study.

• Confirmation of abnormal markers of AD pathology either via a), or alternatively b) mentioned below:

1. Presence in cerebrospinal fluid of (samples taken within past 4 months may be eligible,:

low Aß1-42 concentrations (< 640 pg/mL) and increased total tau concentrations (> 375 pg/ml), or / and low Aß1-42 concentrations (< 640 pg/mL) and increased phospho-tau concentrations (> 52 pg/mL in cerebrospinal fluid), or

2. Abnormal amyloid deposition in a cerebral Positron Emission Tomography (PET) scan. Scans performed in the past according to the recommendation in the protocol are acceptable

• Patients who have not received prescribed drugs for treatment of AD (including acetyl cholinesterase inhibitors (donepezil, galantamine, rivastigmine, tacrine, phenserine) and Memantine within three months prior to screening

• Patients must have at least 6 years of formal education and fluency in the test language as verbally confirmed by the patient and documented by the study investigator.

• Patients must have given written informed consent in accordance with Good Clinical Practice (GCP) and local legislation prior to any study procedures. All patients must be able to give informed consent personally and have capacity for such consent. An informed consent given by a legal representative will not be accepted.

• Patients must have a reliable study partner (per investigator judgement, for instance a family member, partner, guardian etc.)

Exclusion criteria:

• Mild cognitive impairment with any etiology other than prodromal AD (for example:

neurosyphilis, craniocerebral trauma, small vessel disease) based on clinical data and/or current laboratory findings and/or a pre-existing MRI or CT of the brain (CCT). If previous cranial imaging is not available or older than 12 months prior to screening then a CCT or MRI needs to be performed at screening

• Substantial concomitant cerebrovascular disease (defined by a history of a stroke / intracranial haemorrhagia) temporally related to the onset of worsening of cognitive impairment per investigator judgement

• Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years

• Medical history or diagnosis of any of symptomatic and unstable/uncontrolled conditions per investigator judgement

• Severe renal impairment defined with a glomerular filtration rate (GFR) < 30ml/min/1.73m2 in the screening central lab report

• Any other psychiatric disorders such as schizophrenia, or mental retardation

• Any suicidal actions in the past 2 years (per investigator judgement i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behaviour)

• Any suicidal ideation of type 4 or 5 in the Columbia Suicide Severity Rating Scale (C-SSRS) in the past 3 months (i.e. active suicidal thought with intent but without specific plan, or active suicidal thought with plan and intent)

• Previous participation in investigational drug studies of mild cognitive impairment within three months prior to screening. Having received active treatment in any other study targeting disease modification like Aß immunization and tau therapies. Previous participation in studies with non-prescription medications, vitamins or other nutritional formulations is allowed.

• Significant history of drug dependence or abuse (including alcohol, as defined in Diagnostic and Statistical Manual of Mental Disorders [DSM-V] or in the opinion of the investigator) within the last two years, or a positive urine drug screen for cocaine, heroin, or marijuana.

• Known history of HIV infection

• Any planned surgeries requiring general anaesthesia, or hospitalisation for more than 1 day during the study period

• Pre-menopausal women (last menstruation <= 1 year prior to informed consent) who are nursing or pregnant or are of child-bearing potential and are not practicing an acceptable method of birth control

• For male patients: Men who are able to father a child, unwilling to be abstinent or to use an adequate form of effective contraception for the duration of study participation and for at least 28 days after treatment has ended.

• Use of any investigational drug or procedure for other indications within 3 months or 6 half-lives (whichever is longer) prior to randomization.

• Intake of the following medications within 3 months prior to randomization and intended to be initiated during the duration of the trial:

1. tricyclic antidepressants,

2. antidepressants that are monoamine oxidase inhibitors,

3. neuroleptics with moderate or greater anticholinergic potency (e.g. chlorpromazine, fluphenazine, loxapine, perphenazine, thioridazine),

4. anticholinergic medications

The following drugs may be given as needed if the total daily dose was stable 8 weeks prior to randomisation and is expected to be for the duration of the trial:

1. neuroleptics listed in the protocol

2. benzodiazepines and sedatives listed in the protocol

• Clinically significant uncompensated hearing loss in the judgment of the investigator. Use of hearing aids is allowed.

• Known hypersensitivity to the drug product excipients

Related Conditions & MeSH terms

• Alzheimer Disease

Intervention

Drug:
• BI 409306

• Placebo

• BI 409306

• Placebo

• Placebo

• BI 409306

• BI 409306

• Placebo

• Placebo

Locations

Country	Name	City	State
Austria	Landeskrankenhaus Hall, Abt.f. Psychatrie & Psychotherapie A	Hall in Tirol
Austria	Private Practice for Psychiatry and Neurology	Wien
Belgium	Brussels-UNIV Brugmann -Horta	Brussel
Canada	University of Calgary	Calgary	Alberta
Canada	True North Clinical Research Halifax, Inc.	Halifax	Nova Scotia
Canada	True North Clinical Research Kentville, Inc.	Kentville	Nova Scotia
Canada	Institut universitaire de geriatrie Sherbrooke	Quebec
Canada	Toronto Memory Program	Toronto	Ontario
Canada	Royal Jubilee Hospital	Victoria	British Columbia
France	HOP Pierre Wertheimer	Bron
France	HOP Gui de Chauliac	Montpellier
France	HOP Nord Laënnec	Nantes
France	HOP La Pitié Salpêtrière	Paris
France	HOP Jean Bernard, Géria, Poitiers	Poitiers
Germany	emovis GmbH	Berlin
Germany	Praxis Dr. med. Volker Schumann	Berlin
Germany	AFL Arzneimittelforschung Leipzig GmbH	Leipzig
Germany	Zentralinstitut für seelische Gesundheit	Mannheim
Germany	Universitätsklinikum Ulm	Ulm
Germany	Neurologie und Psychiatrie / Psychotherapie	Westerstede
Italy	A.O. Spedali Civili di Brescia	Brescia
Italy	Osp. S. Giovanni di Dio	Firenze
Italy	Policlinico Gemelli	Roma
Netherlands	Brain Research Center	Amsterdam
Poland	Podlassian Center of Psychogeriatry, Bialystok	Bialystok
Poland	Non-Public Outpat. Clinic "Dom Sue Ryder", PALLMED Sp. z o.o	Bydgoszcz
Poland	Mental Health Center Biomed	Kielce
Poland	Non-Public Outpatient Clinic "Synapsa" Pawel Polrola, Kielce	Kielce
Poland	Non-Public Outpatient Clinic Neuro-Kard Ilkowski & Partners	Poznan
Poland	Medical Center Senior	Sopot
Poland	EUROMEDIS Sp. z o.o., Szczecin	Szczecin
Poland	Reg. Specialist Hospital Wroclaw, Research & Develop. Center	Wroclaw
Portugal	Hospital Fernando Fonseca, EPE	Amadora
Portugal	CHUC - Centro Hospitalar e Universitário de Coimbra, EPE	Coimbra
Portugal	CHLN, EPE - Hospital de Santa Maria	Lisboa
Portugal	CHLO, EPE - Hospital Egas Moniz	Lisboa
Spain	Hospital Universitario Fundación Alcorcón	Alcorcon (Madrid)
Spain	Hospital Clínic de Barcelona	Barcelona
Spain	Hospital Santa Creu i Sant Pau	Barcelona
Spain	Hospital Universitario Virgen de la Arrixaca	El Palmar (murcia)
Spain	Hospital Universitari General de Catalunya	Sant Cugat del Vallès
Spain	Hospital Mútua Terrassa	Terrasa (Barcelona)
United Kingdom	Royal United Hospital	Bath
United Kingdom	Derriford Hospital	Plymouth
United Kingdom	Re-Cognition Health	Plymouth
United States	ANI Neurology, PLLC, dba Alzheimer's Memory Center	Charlotte	North Carolina
United States	Memory Enhancement Center of America, Inc.	Eatontown	New Jersey
United States	Orange County Neuropsychiatric Research Center LLC	Orange	California
United States	California Neuroscience Research	Sherman Oaks	California
United States	Richmond Behavioral Associates	Staten Island	New York
United States	Tulsa Clinical Research, LLC	Tulsa	Oklahoma
United States	Premiere Research Institute	West Palm Beach	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Countries where clinical trial is conducted

United States,  Austria,  Belgium,  Canada,  France,  Germany,  Italy,  Netherlands,  Poland,  Portugal,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment.	Neuropsychological Test Battery (NTB) response, defined as change from baseline in total z-score after 12 weeks of treatment. The NTB Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean at baseline. Negative numbers indicate values lower than baseline and positive numbers indicate values higher than baseline. Change from baseline will be calculated as the post-baseline composite z-score minus the pre-treatment z-score, such that a positive change indicates an improvement from baseline	Baseline and 12 weeks
Primary	Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment From Two Twin Trials, Present 1289.5 (NCT02240693) and 1289.7 (NCT02337907)	Neuropsychological Test Battery (NTB) response, defined as change from baseline in total z-score after 12 weeks of treatment. The NTB Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean at baseline. Negative numbers indicate values lower than baseline and positive numbers indicate values higher than baseline. Change from baseline will be calculated as the post-baseline composite z-score minus the pre-treatment z-score, such that a positive change indicates an improvement from baseline	Baseline and 12 weeks
Secondary	Change From Baseline in ADCS-MCI-ADL (Alzheimer's Disease Cooperative Study/Activities of Daily Living for Patients With Mild Cognitive Impairment) Total Score After 12-week Treatment	Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS-ADL) is a rating scale used to assess basic and instrumental activities of daily living. In the full version of the scale, 23 items are rated by the investigator using information supplied by the caregiver.; Each item has a score range varying from 0-3 to 0-5. The sum score can range from 0 to 78. Higher scores indicate better function.; Least Squares Mean is actually an adjusted mean change from baseline.	Baseline and 12 weeks
Secondary	Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) Total Score After 12-week Treatment	The CDR-SB is obtained through semi-structured interviews of patients and informants, and cognitive functioning was rated in 6 domains of functioning: memory, orientation, judgment and problem solving, community affairs, home and hobbies and personal care.; Each domain was rated on a 5-point scale of functioning as follows: 0-no impairment; 0.5-questionable impairment; 1-mild impairment; 2-moderate impairment and 3-severe impairment. Only personal care was scored on a 4-point scale without a 0.5 rating available. The higher the score, the greater the severity of dementia. Least Squares Mean is actually an adjusted mean change from baseline.	Baseline and 12 weeks
Secondary	Change From Baseline in Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog11) Total Score After 12-week Treatment	Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog11) is an 11-item cognitive subscale that objectively measures memory, language, orientation, and praxis with a total score range of 0 to 70. The greater the dysfunction, the greater the score. Least Squares Mean is actually an adjusted mean change from baseline.	Baseline and 12 weeks

External Links

•   Link